GlycoEra AG

📍 Wädenswil, Switzerland🗓 Founded 2020👥 35 employees💰 Last funded Dec 2021
Biotechnology Research🌐 glycoera.com
Website LinkedIn
GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiND™ platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein of interest regardless of therapeutic area – such as an autoantibody in autoimmune disease, a circulating factor inducing inflammation or a protein aggregate in neurological disease.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
1
United States
1
Frequently asked questions
Who invested in GlycoEra AG?
GlycoEra AG has 2 investors on record on gritt.io, including 2 early-stage backers.
When did GlycoEra AG last raise funding?
The most recent investment in GlycoEra AG recorded on gritt.io was in December 2021.
When was GlycoEra AG founded?
GlycoEra AG was founded in 2020.
What industry is GlycoEra AG in?
GlycoEra AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is GlycoEra AG based?
GlycoEra AG is headquartered in Wädenswil, Switzerland.